| Literature DB >> 34222675 |
Hossein Abdolrahimzadeh Fard1, Roham Borazjani1, Golnar Sabetian2, Zahra Shayan3, Shahram Boland Parvaz1, Hamid Reza Abbassi1, Shiva Aminnia4, Maryam Salimi4, Shahram Paydar1, Ali Taheri Akerdi1, Masome Zare5, Leila Shayan1, Salahaddin Mahmudi-Azer1.
Abstract
OBJECTIVES: The triage of trauma patients with potential COVID-19 remains a major challenge given that a significant number of patients may be asymptomatic or pre-symptomatic. This study aimed to compare the specificity and sensitivity of available triage systems for COVID-19 among trauma patients. Furthermore, it aimed to develop a novel triage system for SARS-CoV-2 detection among trauma patients in centers with limited resources.Entities:
Keywords: COVID-19; diagnosis; multiple trauma; triage
Year: 2021 PMID: 34222675 PMCID: PMC8212155 DOI: 10.1136/tsaco-2021-000726
Source DB: PubMed Journal: Trauma Surg Acute Care Open ISSN: 2397-5776
Definition of suspicious COVID-19 cases, according to WHO, MOHME, and ECDC protocols.
| Protocols | Case definition |
| WHO | Suspected case of SARS-CoV-2 infection: Patient who meets clinical criteria above AND is a contact of a probable or confirmed case, or linked to a COVID-19 cluster. Suspect case with chest imaging showing findings suggestive of COVID-19 disease. Person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause. Death, not otherwise explained, in an adult with respiratory distress preceding death AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster. Person with a positive Nucleic Acid Amplification Test (NAAT). Person with a positive SARS-CoV-2 antigen-RDT AND meeting either the probable case definition or suspect criteria A or B. An asymptomatic person with a positive SARS-CoV-2 antigen-RDT who is a contact of a probable or confirmed case. |
| MOHME | Suspicious case A person with severe febrile respiratory disease who needs to be hospitalized due to fever, cough, etc, and another pathogen to justify his disease’s symptoms is not conceivable. History of travel to endemic area within 14 days before the onset of symptoms Be one of the healthcare providers Despite appropriate pneumonia treatments, the clinical response is inadequate, and the clinical condition is unusual and unexpected. |
| ECDC | Confirmed case: |
COVID-19, coronavirus disease 2019; ECDC, European Centres for Disease Control; MOHME, Iranian Ministry of Health and Medical Education; RDT, rapid diagnostic test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Demographic data and clinical histories of the suspicious cases (n=132)
| Variables | RT-PCR +ve (n=30) | RT-PCR −ve (n=102) | P value |
| Sex; number (%) | |||
| Male | 24 (80%) | 78 (76.5%) | – |
| Female | 6 (20%) | 24 (23.5%) | – |
| M/F | 4 | 3.25 | 0.68 |
| Nationality; number (%) | |||
| Iranian | 27 (90%) | 92 (90.2%) | 0.97 |
| Non-Iranian | 3 (10%) | 10 (9.8%) | |
| COVID-19 related history; number (%) | |||
| Close contact | 7 (23.3%) | 5 (4.9%) | |
| Fever | 10 (33.3%) | 32 (31.4%) | 0.83 |
| Cough | 6 (20%) | 11 (10.8%) | 0.18 |
| Respiratory distress | 16 (53.3%) | 13 (12.7%) | |
| Neurological symptoms* | 5 (16.7%) | 6 (5.9%) | 0.06 |
| Abdominal pain | 3 (10%) | 0 | |
| Anorexia | 1 (3.3%) | 10 (9.8%) | 0.22 |
| Past medical history; number (%) | |||
| Cancer | 2 (6.7%) | 0 | 0.05 |
| DM | 3 (10%) | 6 (5.9%) | 0.43 |
| Chronic anemia | 1 (3.3%) | 0 | 0.22 |
| Cardiac disease | 3 (10%) | 7 (6.9%) | 0.56 |
| CKD | 0 | 1 (1%) | 1.0 |
| Asthma | 0 | 2 (2%) | 1.0 |
| COPD | 2 (6.7%) | 0 | 0.05 |
| HTN | 4 (13.3%) | 8 (7.8%) | 0.35 |
| Hospital course; number (%) | |||
| Intubation | 11 (36.7%) | 38 (37.3%) | 0.95 |
| Mortality | 5 (16.7%) | 11 (10.8%) | 0.38 |
| ALOS (days); mean (SD) | 8.1 (5.6) | 10.66 (13.66) | 0.63 |
*Defined as the presence of any of the followings: anosmia, dysgeusia, ageusia.
ALOS, average length of hospital stay; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; M/F, male to female ratio; RT-PCR, reverse transcription-polymerase chain reaction; −ve, negative; +ve, positive.
Figure 1In our triage model, patients with unstable vital signs, decreased LOC, and in need of life-saving surgeries were considered suspicious for COVID-19 and transferred to special wards after proper resuscitation. In the second step, other patients who did not meet the above criteria, were assessed using their medical histories, epidemiological risk factors (as subjective parameters) and body temperature, respiratory rate (RR), and oxygen saturation (as objective parameters). In the third step, we evaluated individuals according to the obtained laboratory data for evaluating asymptomatic carriers. All other patients were transferred to regular wards and were closely monitored for signs and symptoms of COVID-19. All patients admitted to the ICU wards and those who developed COVID-19 related symptoms were also evaluated during their hospital course using RT-PCR. *A negative result was repeated 4 days later from the lower respiratory tract. **All ICU-admitted patients: evaluated by RT-PCR test. +Two times in 30 min. β, according RSNA classification. CBC, complete blood count; CRP, C-reactive peptide; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; LOC, level of consciousness; RSNA, Radiological Society of North America; RT-PCR, reverse transcription-polymerase chain reaction.
Diagnostic capability of available protocols in detecting COVID-19 among trauma patients
| Protocols | RT-PCR | Sensitivity (%) | Specificity (%) | ||
| +ve (n=30) | −ve (n=610) | ||||
| WHO | Suspicious | 4 | 0 | 13.3 | 100 |
| Non-suspicious | 26 | 610 | |||
| MOHME | Suspicious | 7 | 1 | 23.3 | 99 |
| Non-suspicious | 23 | 609 | |||
| ECDC (possible) | Suspicious | 28 | 64 | 93.3 | 89.5 |
| Non-suspicious | 2 | 546 | |||
| ECDC (probable) | Suspicious | 7 | 1 | 23.3 | 99 |
| Non-suspicious | 23 | 609 | |||
| Our stepwise triage system | Suspicious | 28 | 59 | 93.3 | 90.3 |
| Non-suspicious | 2 | 551 | |||
ECDC, European Centre for Disease Control and Prevention; MOHME, Iranian Ministry of Health and Medical Education; RT-PCR, reverse transcription-polymerase chain reaction; +ve, positive; −ve, negative.
Frequency of positive clinical and laboratory findings in suspected patients (n=130)
| Stages | Detected patients (%) | RT-PCR (n=30) |
| Stage 1 | 54 (40.9%) | 17 (56.7%) |
| 1. Decrease in LOC | 24 (18.2) | 7 (23.3%) |
| 2. Unstable hemodynamics | 32 (24.2) | 9 (30%) |
| 3. Life-saving surgery | 5 (3.8%) | 1 (3.3%) |
| 4. Both 1 and 2 | 5 (3.8%) | 3 (10%) |
| 5. Both 1 and 3 | 2 (1.5%) | 1 (3.3%) |
| Stage 2 | 40 (30.3%) | 9 (30%) |
| 1. History of respiratory symptoms | 25 (18.9%) | |
| 2. Epidemiological factors | 9 (6.8%) | |
| 3. Fever | 20 (15.2%) | |
| 4. RR >20 | 21 (15.9) | |
| 5. Sat O2 | 51 (38.6%) | |
| Stage 3 | 14 (10.6%) | 0 (0%) |
| 1. Leukocytosis | 23 (17.4%) | |
| 2. Lymphopenia | 27 (20.5%) | |
| 3. High ESR | 13 (9.8%) | |
| 4. High CRP | 23 (17.4%) | |
| Stage 4 | 22 (16.7%) | 2 (6.7%) |
| 1. Fever | 2 (1.5%) | 2 (6.7%) |
CRP, C-reactive peptide; ESR, erythrocyte sedimentation rate; LOC, level of consciousness; RR, respiratory rate; RT-PCR, reverse transcription-polymerase chain reaction.